hepatocellular%20carcinoma
HEPATOCELLULAR CARCINOMA

Hepatocellular carcinoma is malignancy that originates from the liver.

Physical signs are hepatomegaly and ascites. It is usually asymptomatic for much of its natural history.

Liver cancer is the second most common cause of cancer-related mortality worldwide & hepatocellular carcinoma accounts for >90% of liver cancers.

 

Hepatocellular Carcinoma References

  1. Bruix J, Sherman M, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology. 2011 Mar;53(3):1020-1022. doi: 10.1002/hep.24199. PMID: 21374666
  2. Chow PK, Choo SP, Ng DC, et al. National Cancer Centre Singapore Consensus guidelines for hepatocellular carcinoma. Liver Cancer. 2016 Apr;5(2):97-106. doi: 10.1159/000367759. PMID: 27386428
  3. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018 Jul;69(1):182-236. doi: 10.1016/j.jhep.2018.03.019. PMID: 29628281
  4. European Association for the Study of the Liver; European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012 Apr;56(4):908-943. doi: 10.1016/j.jhep.2011.12.001. PMID: 22424438
  5. Heimbach JK, Kulik LM, Finn RS, et al. American Association for the Study of Liver Diseases (AASLD) guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018 Jan;67(1):358-380. doi: 10.1002/hep.29086.
  6. National Comprehensive Cancer Network. Hepatobilliary cancers. Version 1.2018. NCCN. https://www.nccn.org/. Feb 2018.
  7. Omata M, Cheng AL, Kokudo N, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017 Jul;11(4):317-370. doi: 10.1007/s12072-017-9799-9. PMID: 28620797
  8. Verslype C, Rosmorduc O, ESMO Guidelilnes Working Group, et al. Hepatocellular carcinoma: ESMO–ESDO Clinical practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012 Oct;23(Suppl 7):vii41-vii48. doi: 10.1093/annonc/mds225. PMID: 22997453
  9. Yu SJ. A concise review of updated guidelines regarding the management of hepatocellular carcinoma around the world: 2010-2016. Clin Mol Hepatol. 2016 Mar;22(1):7-17. doi: 10.3350/cmh.2016.22.1.7. PMID: 27044761
  10. Cancer Research UK. BCLC staging system and the Child-Pugh system. Cancer Research UK. https://www.cancerresearchuk.org/. Jan 2019.
  11. Chen LT, Martinelli E, Cheng AL, et al. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO. Ann Oncol. 2020 Mar;31(3):334–351. doi:10.1016/j.annonc.2019.12.001. PMID: 32067677
  12. He MK, Le Y, Li QJ, et al. Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma: a prospective non-randomized study. Chin J Cancer. 2017 Oct;36(1):83. doi: 10.1186/s40880-017-0251-2. PMID: 29061175
  13. Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018 Aug;68(2):723–750. doi: 10.1002/hep.29913. PMID: 29624699
  14. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: hepatobiliary cancers. Version 4.2019. NCCN. https://www.nccn.org/. Dec 2019.
  15. Saeki I, Yamasaki T, Maeda M, et al. Treatment strategies for advanced hepatocellular carcinoma: Sorafenib vs hepatic arterial infusion chemotherapy. World J Hepatol. 2018 Sep;10(9):571–584. doi: 10.4254/wjh.v10.i9.571. PMID: 30310535
  16. Vogel A, Cervantes A, Chau I, et al. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018 Oct;29(Suppl 4):iv238–iv255. doi: 10.1093/annonc/mdy308. PMID: 30285213
  17. Cheng AL, Qin S, Ikeda M, et al. IMBrave 150: Efficacy and safety results from a ph III study evaluating atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (Sor) as first treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC). Ann Oncol. 2019 Nov;30(Suppl 9):ix86-ix87.
  18. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology (NCCN guidelines): Hepatobiliary cancers. Version 2.2020. NCCN. https://www.nccn.org/. 08 May 2020.
  19. Yau T, Kang YK, Kim TK, et al. Nivolumab (NIVO) + Ipilimumab (IPI) combination therapy in patients with advanced hepatocellular (aHCC): Results from CheckMate 040. J Clin Oncol. 2019 May;37(Suppl 15):4012-4012. doi:10.1200/JCO.2019.37.15_suppl.4012.
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Hepatology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 18 Nov 2020
The distribution of body fat contributes to the risk of coronary heart disease (CHD), with the risk of cardiovascular events further increasing among individuals with low liver fat (LF) and high visceral adipose tissue (VAT) or abdominal fat, results of a recent study have shown.
Tristan Manalac, 17 Nov 2020
Adding dapagliflozin (DAPA) and saxaglipitin (SAXA) to routine metformin treatment in type 2 diabetes (T2D) leads to a decrease in liver fat and adipose tissue, according to a new study presented at The Liver Meeting Digital Experience by the American Association for the Study of Liver Diseases (AASLD 2020).
Jairia Dela Cruz, 18 Nov 2020
The small molecule fatty acid synthase inhibitor TVB-2640 boasts a win in addressing the three key drivers of nonalcoholic steatohepatitis (NASH)—namely liver fat, fibrosis, and inflammation—in the phase II FASCINATE-1 trial presented during The Liver Meeting Digital Experience of the American Association for the Study of Liver Diseases (AASLD).